StockCIK 1833141
Helus Pharma Inc. (HELP): Insider Trades and Fund Holdings
In the past 12 months, Helus Pharma Inc. insiders reported 9 open-market purchases worth $9.67M and 0 sales worth $0.
9Insider buys, 12 months
$9.67MBought by insiders, 12 months
$0Sold by insiders, 12 months
0Tracked funds holding
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 1, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Oct 1 | Greg CaversCFO | ▲ BUY | $39K |
| Sep 21 | Michael HalsteadCEO | ▲ BUY | $1.35M |
| Sep 11 | Paul GlavineChief Growth Officer | ▲ BUY | $1.25M |
| Sep 11 | Paul GlavineChief Growth Officer | ▲ BUY | $1.25M |
| Sep 11 | Eric H. L. SoExecutive Chair | ▲ BUY | $1.24M |
| Sep 10 | Eric H. L. SoExecutive Chair | ▲ BUY | $1.21M |
| Sep 10 | Paul GlavineChief Growth Officer | ▲ BUY | $1.18M |
| Sep 9 | Eric H. L. SoExecutive Chair | ▲ BUY | $1.12M |
| Sep 9 | Paul GlavineChief Growth Officer | ▲ BUY | $1.04M |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Greg Cavers | CFO | 1 | $39K | 0 | $0 |
| Michael Halstead | CEO | 1 | $1.35M | 0 | $0 |
| Paul Glavine | Chief Growth Officer | 4 | $4.72M | 0 | $0 |
| Eric H. L. So | Executive Chair | 3 | $3.57M | 0 | $0 |
ADVERTISEMENT
320 × 100 ad slot
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →